The global genomics landscape has undergone a tectonic shift, with China-based DNA sequencing service factories emerging as the backbone of high-throughput genetic research. As we enter the era of precision medicine, the demand for cost-effective, high-accuracy Next-Generation Sequencing (NGS) has skyrocketed. Chinese suppliers have successfully bridged the gap between cutting-edge innovation and large-scale industrial output.
Shenzhen BioX Medical Co., Ltd. stands at the forefront of this revolution. Established in 2017 and headquartered in Shenzhen—the "Silicon Valley of Hardware" and a global biotech hub—BioX Medical has built a reputation for excellence in molecular diagnostic analysis and genetic testing solutions.
Sqm Facility
Expert Staff
Established
Countries Served
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, and biotechnology companies worldwide.
From reagent formulation to automated PCR hardware, Chinese suppliers offer a complete ecosystem, reducing lead times and ensuring component compatibility.
Economies of scale allow for highly competitive pricing without compromising the analytical depth required for complex genomic studies.
Rapid prototyping of automated laboratory testing systems and pathogen detection solutions keeps pace with emerging viral threats and clinical needs.
Shenzhen BioX Medical provides flexible OEM and ODM services for distributors and diagnostic companies seeking customized molecular testing solutions.
In the DNA sequencing sector, Reliability and Trustworthiness are paramount. Modern DNA sequencing services must navigate complex regulatory environments. China’s leading suppliers have matured significantly, adopting international standards to ensure global interoperability.
By integrating advanced automation and precision medicine support technologies, BioX Medical develops solutions designed to improve testing efficiency and operational reliability.
The transition from Sanger sequencing to Third-Generation Sequencing and beyond is driving new application scenarios. We are seeing a move towards "Sequencing Everything, Everywhere."
Non-invasive cancer detection using cfDNA/ctDNA analysis, requiring high-sensitivity sequencing platforms.
Enhancing crop resilience and livestock health through genomic selection and marker-assisted breeding.
Rapid pathogen detection and variant tracking during pandemics, utilizing Biobase PCR and automated analysis systems.
BioX Medical's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, and pathogen detection solutions. These are essential for the global evolution of laboratory medicine.
Committed to advancing modern laboratory technologies, BioX Medical focuses on delivering reliable, scalable, and innovative diagnostic systems that support disease detection, genetic analysis, clinical research, and precision healthcare initiatives. Through continuous technological advancement and customer-oriented development, the company strives to contribute to the global evolution of molecular diagnostics and laboratory medicine.
BioX Medical
